Lupin Ltd Share Price
(LUPIN)
₹2012.8▲2.21%
as on 04:02PM, 15 Apr 2025
Lupin Performance
Day's Low
Day's High
₹1,980.3Day's Price Range₹2,03052 Week's Low
52 Week's High
₹1,493.352-Week Price Range₹2,402.9
| Returns % | |
| 1 Month Return | -1.13 % |
| 3 Month Return | -7.49 % |
| 1 Year Return | + 22.38 % |
| Market Stats | |
| Previous Close | ₹1,969.25 |
| Open | ₹2,030.00 |
| Volume | 12.50L |
| Upper Circuit | ₹2,166.20 |
| Lower Circuit | ₹1,772.40 |
| Market Cap | ₹89,909.07Cr |
Lupin Fundamentals
P/E Ratio
31.3
PEG Ratio
1.33
Market Cap
₹89,909.07 Cr
P/B Ratio
3.58
EPS
42.47
Dividend Yield
0.49
Sector
Pharmaceuticals
ROE
11.92
Mutual Fund Holdings of Lupin
Lupin Analyst Rating
based on 36 analysts
58.33%
Buy
30.56%
Hold
11.11%
Sell
Based on 36 analysts offering long term price targets for Lupin. An average target of ₹2299.17
Source: S&P Global Market Intelligence
Lupin Share analysis
Lupin price forecast by 36 analysts
Upside of16.75%
High
₹2800
Target
₹2299.17
Low
₹1900
Lupin target price ₹2299.17, a slight upside of 16.75% compared to current price of ₹2012.8. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:34.84%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:111.50%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Lupin Ltd
Lupin Receives Positive USFDA Inspection Report - 10 Apr, 2025
Lupin Ltd announced the closure of all outstanding USFDA inspections at its Aurangabad facility with the receipt of an establishment inspection report. Despite a broader drop in pharma stocks due to tariff concerns, analysts remain optimistic about Lupin's market position.Lupin Digital Health Expands Patient Base Significantly - 08 Apr, 2025
Lupin Digital Health has doubled its patient base to 10,000 and aims for 50,000 by year-end. The platform focuses on cardiac rehabilitation and prevention, leveraging partnerships and innovative digital solutions.Lupin Reports Strong Q3 FY25 Earnings Growth - 06 Apr, 2025
Lupin's Q3 FY25 earnings show a 10.6% YoY revenue increase to Rs 5,618.6 crore and a 38.81% rise in net profit to Rs 858.86 crore. The company maintains strong U.S. sales and received multiple FDA approvals, despite facing competitive pressures and currency fluctuations. Promoter stake remains stable at 45.41%, indicating confidence in growth.Lupin Expands UK Presence with Renascience Acquisition - 02 Apr, 2025
Lupin Limited has acquired UK-based Renascience Pharma for £12.3 million, strengthening its portfolio in specialty pharmaceuticals and expanding its market presence in the UK.Lupin Board Approves Key Business Transfers - 31 Mar, 2025
Lupin Ltd's board has approved the transfer of its API R&D division to a wholly owned subsidiary and modified the OTC business transfer to LUPINLIFE Consumer Healthcare Ltd.Concerns Over US Tariffs Impacting Indian Pharma - 30 Mar, 2025
The Indian pharma sector, including Lupin Ltd, faces challenges due to a 10% tariff on US pharma imports, raising concerns among industry groups about cost burdens on distributors and generic manufacturers.Lupin Stock Experiences Bullish Signals and Decline - 25 Mar, 2025
Lupin Ltd shows bullish momentum with a target price of ₹2,284 and strong support at ₹1,985. However, the stock fell by 3.2% to ₹2,054, indicating volatility.Lupin Digital Health Launches Cardiac Care Guide - 22 Mar, 2025
Lupin Digital Health has introduced a comprehensive Post-Procedure Home-Based Care Guide for cardiac patients, developed with the American College of Cardiology, to enhance recovery and reduce hospital readmissions.Lupin's Subsidiary Wins Prestigious CMO Award - 21 Mar, 2025
Nanomi B.V., a subsidiary of Lupin Limited, has been awarded the CMO Award for Life Science Leadership in Drug Delivery during the DCAT week in New York.Lupin Gains USFDA Approval for Amifampridine Tablets - 17 Mar, 2025
Lupin Ltd received tentative approval from the USFDA for Amifampridine Tablets, allowing entry into the market for treating Lambert-Eaton myasthenic syndrome. This approval strengthens Lupin's manufacturing capabilities and expands its portfolio in key therapeutic areas, with significant market potential indicated by Firdapse's $306 million sales in 2024.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 4 quarters, 359.43 Cr → 855.16 Cr (in ₹), with an average increase of 20.5% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 21.50% to 22.04% in Dec 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.89% to 16.92% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 4.99K Cr → 5.82K Cr (in ₹), with an average increase of 4.9% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 50.4% return, outperforming this stock by 28.0%
NEGATIVE IMPACTPrice Dip
In the last 7 days, LUPIN stock has moved down by -0.7%
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 46.96% to 46.95% in Dec 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.44% to 6.26% in Dec 2024 quarter
Lupin Financials
Lupin Index Inclusions
Lupin Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.95% | ||
| Foreign Institutions | 22.04% | 2.52 | |
| Mutual Funds | 16.92% | 0.20 | |
| Retail Investors | 6.26% | ||
| Others | 7.82% |
Lupin Key Indicators
Lupin Valuation
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (31.30x)
April 11, 2025
Industry (50.30x)
April 11, 2025
Highest (517.33x)
December 2, 2022
Lupin Earnings and Dividends
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 39.48% since last year same period to ₹855.16Cr in the Q3 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 0.3% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.60%.
Read More about Dividends
Lupin Technicals Summary
Bearish
Neutral
Bullish
Lupin Ltd is currently in a Bearish trading position according to technical analysis indicators.
Lupin Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹89,909.07 Cr | 28.6% | 0.51 | ₹1,935 Cr | ₹20,010 Cr | |
| BUY | ₹14,277.68 Cr | -3.51% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹63,424.92 Cr | 22.06% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹87,426.64 Cr | 31.24% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹62,987.34 Cr | 14.65% | 0.53 | NA | NA |
About Lupin
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Revenue: ₹5,618.56Cr as on December 2024 (Q4 24)
Net Profit: ₹858.86Cr as on December 2024 (Q4 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Lupin Ltd
What is Lupin Ltd price today?
Lupin Ltd share price today stands at ₹2012.8, Open: ₹2030, Previous Close: ₹1969.25, High: ₹2030, Low: ₹1980.3, 52 Week High: ₹2402.9, 52 Week Low: ₹1493.3.
How to Buy Lupin Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Lupin Ltd shares
What are today's traded volumes of Lupin Ltd?
Today's traded volume of Lupin Ltd(LUPIN) is 12.50L.
What is today's market capitalisation of Lupin Ltd?
Today's market capitalisation of Lupin Ltd(LUPIN) is ₹89909.07Cr.
What is the 52 Week High and Low Range of Lupin Ltd?
How much percentage Lupin Ltd is down from its 52 Week High?
Lupin Ltd (LUPIN) share price is ₹2012.8. It is down -16.23% from its 52 Week High price of ₹2402.9
How much percentage Lupin Ltd is up from its 52 Week low?
Lupin Ltd (LUPIN) share price is ₹2012.8. It is up 34.79% from its 52 Week Low price of ₹1493.3